ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster…
Immunology
-
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
-
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody DR-0201 in a deal…
-
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune…
-
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
-
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer…
-
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The chronic obstructive pulmonary disease (COPD) market continues its trajectory of rapid growth, bolstered by significant advancements in biologics and…
-
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is characterised by progressive muscle degeneration and weakness, and is…
-
Palforzia’s peanut allergy treatment use in Europe expanded to toddlers
The European Commission (EC) has approved the extension of Stallergenes Greer’s Palforzia (defatted powder of Arachis hypogaea L., semen (peanut))…
-
Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
US-based Candid Therapeutics has signed another T-cell engager (TCE) partnership, this time with Chinese biotech WuXi Biologics for the global…
